As part of its ongoing global investment program, Lincotek Medical has completed a new 350-square-meter area dedicated to Air Plasma Spray/APS coating production at its Trento, Italy facility. This investment allows Lincotek Medical to create flexibility, reduce lead times and follow market growth.
The production facility is designed to address the most stringent global medical standards and safety rules, guided by the latest European directives and ATEX.
Up to three new APS systems can be fitted in the new space in Trento. Two have already been installed, along with an automatic sandblasting machine created by Lincotek Equipment.
The new APS lines were built using the Lincotek Equipment twin approach, allowing for movement from one line to another and coating to the identical parameters, by moving the production programs. Assuming customer validation, this may significantly reduce time to markets on a global basis and speed up eventual mitigation needs.
Most of the validation activities are now close to completion and the new production facility is expected to go live before the end of September 2020.
“It’s not been an easy time for many companies, given the challenges of COVID-19,” said Gennaro D’Andrea, General Manager of Lincotek Medical Division. “We’re committed to providing the best possible service to the Orthopedic OEMs and continue to invest with the future in mind. We intend to provide real partnership to our customers and have the infrastructure and resources to meet their changing requirements.”
Lincotek Medical is a fully-integrated, global contract manufacturer for orthopedic, trauma, spine and dental markets, with expertise in casting, machining, plasma spray coatings and additive manufacturing technologies in the medical field.